The lawsuit in Greece comes two years after the company paid the U.S. Department of Justice and the Securities and Exchange Commission $345 million to settle foreign bribery claims in several countries including Greece.
The anticipated Greek lawsuit against Novartis has been filed, with the country asking for 214 million euros in compensation from the pharmaceutical giant.
Greek Health Minister Thanos Plevris said in a statement that the Greek state is seeking compensation for the damage it has suffered “from the actions that Novartis itself has admitted to in the USA that concerns payments to doctors.” The minister added that the state reserves the right to claim any damage it has suffered with a newer lawsuit and is clear that “all sanctions against Novartis for its illegal practices will be applied,” a Greek news outlet reports.
The illegal practices alleged include bribes to former government officials and healthcare providers to drive up Novartis sales in the country. The lawsuit comes two years after the company paid the U.S. Department of Justice and the Securities and Exchange Commission $345 million to settle foreign bribery claims in several countries including Greece.
In the U.S. settlement, Novartis admitted it had used medical events and an academic study to bribe Greek officials and healthcare providers. Since the U.S. government has collected settlement money from the company, Greece wants a piece of the justice pie, too.
Novartis has had it rough lately. Just this month, a hacking group posted data allegedly from the company, although the drugmaker said no sensitive data were compromised.
By Zoey Becker
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).